Cystic Fibrosis - Pipeline Review, H1 2020

April 2020 | 502 pages | ID: CC268F2729CEN
Global Markets Direct

Abstracts

Cystic Fibrosis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cystic Fibrosis - Pipeline Review, H1 2020, provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose and severe constipation. Risk factors include family history and race (Northern European ancestry). Treatment includes antibiotics, mucus-thinning, bronchodilators and oral pancreatic enzymes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cystic Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 34, 20, 1, 67, 32 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Cystic Fibrosis (Respiratory).
• The pipeline guide reviews pipeline therapeutics for Cystic Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Cystic Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Cystic Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Cystic Fibrosis (Respiratory)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Cystic Fibrosis (Respiratory).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Cystic Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Cystic Fibrosis - Overview
Cystic Fibrosis - Therapeutics Development
Cystic Fibrosis - Therapeutics Assessment
Cystic Fibrosis - Companies Involved in Therapeutics Development
Cystic Fibrosis - Drug Profiles
Cystic Fibrosis - Dormant Projects
Cystic Fibrosis - Discontinued Products
Cystic Fibrosis - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Cystic Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Companies, H1 2020 (Contd..8), H1 2020
Products under Development by Companies, H1 2020 (Contd..9), H1 2020
Products under Development by Universities/Institutes, H1 2020
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Cystic Fibrosis - Pipeline by 4D Molecular Therapeutics Inc, H1 2020
Cystic Fibrosis - Pipeline by AbbVie Inc, H1 2020
Cystic Fibrosis - Pipeline by Abeona Therapeutics Inc, H1 2020
Cystic Fibrosis - Pipeline by Agile Sciences Inc, H1 2020
Cystic Fibrosis - Pipeline by AGILeBiotics BV, H1 2020
Cystic Fibrosis - Pipeline by Airway Therapeutics LLC, H1 2020
Cystic Fibrosis - Dormant Projects, H1 2020
Cystic Fibrosis - Discontinued Products, H1 2020
Cystic Fibrosis - Discontinued Products, H1 2020 (Contd..1), H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Cystic Fibrosis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

4D Molecular Therapeutics Inc
AbbVie Inc
Abeona Therapeutics Inc
Agile Sciences Inc
AGILeBiotics BV
Airway Therapeutics LLC
Alaxia SAS
AlgiPharma AS
Altavant Sciences Inc
Amgen Inc
Antabio SAS
Arch Biopartners Inc
Arcturus Therapeutics Ltd
Armata Pharmaceuticals Inc
Arrevus Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Atlantic Healthcare Plc
Avidin Ltd
BioAegis Therapeutics Inc
Biofilm Pharma
Biolytx Pharmaceuticals Corp
Boehringer Ingelheim International GmbH
Boston Pharmaceuticals Inc
Breathe Easy Therapeutics Ltd
BridgeBio Pharma Inc
Calista Therapeutics Inc
Calithera Biosciences Inc
Catabasis Pharmaceuticals Inc
Celtaxsys Inc
Chiesi Farmaceutici SpA
Chrysalis Pharma SAS
Cilian AG
Copernicus Therapeutics Inc
Corbus Pharmaceuticals Inc
CRISPR Therapeutics AG
CrowdOut Therapeutics
CSA Biotechnologies LLC
Cyclacel Pharmaceuticals Inc
Cyclenium Pharma Inc
Daiichi Sankyo Co Ltd
Destiny Pharma Plc
DiscoveryBiomed Inc
Druggability Technologies Holdings Ltd
Editas Medicine Inc
Eloxx Pharmaceuticals Inc
EmphyCorp Inc
EnBiotix Inc
Enterprise Therapeutics Ltd
Entrinsic Health Solutions, Inc.
Enzyvant Sciences Ltd
Errant Gene Therapeutics LLC
Evaxion Biotech ApS
Evotec SE
Exotect LLC
Galapagos NV
Galenus Therapeutics Inc
Generation Bio Corp
Genzyme Corp
Grupo Praxis Pharmaceutical SA
Helperby Therapeutics Group Ltd
Horizon Therapeutics PLC
Icagen Inc
Idorsia Pharmaceutical Ltd
Immun System IMS AB
Insmed Inc
Invion Ltd
Ionis Pharmaceuticals Inc
Kamada Ltd
Kither Biotech Srl
Kyorin Pharmaceutical Co Ltd
Lakewood-Amedex Inc
Lamellar Biomedical Ltd
Laurent Pharmaceuticals Inc
MannKind Corp
Mariposa Health Ltd
Microbion Corp
Mucokinetica Ltd
Nanogenics Ltd
Neupharma Srl
New Amsterdam Sciences Inc
Novabiotics Ltd
Novartis AG
Novoteris LLC
Omnispirant Ltd
Orphomed Inc
OrPro Therapeutics Inc
Oryn Therapeutics
Paranta Biosciences Ltd
Parion Sciences Inc
Pharmaero ApS
Pharmaxis Ltd
PhaseBio Pharmaceuticals Inc
Polyphor AG
Progenra Inc
ProQR Therapeutics NV
Protalix BioTherapeutics Inc
Proteostasis Therapeutics Inc
Pulmatrix Inc
Rare Partners Srl
Recode Therapeutics Inc
Renovion Inc
Riptide Bioscience Inc
Santhera Pharmaceuticals Holding AG
SciBac Inc
Sequoia Sciences Inc
Silurian Pharmaceuticals Inc
SolAeroMed Inc
Specific Biologics Inc
Spirovant Sciences Inc
Spyryx Biosciences Inc
Synedgen Inc
Synovo GmbH
Synspira LLC
Takeda Pharmaceutical Co Ltd
TGV-Inhalonix Inc
Therapeutic Systems Research Laboratories Inc
Translate Bio Inc
Trucode Gene Repair Inc
Vast Therapeutics Inc
Vectura Group Plc
Verona Pharma Plc
Vertex Pharmaceuticals Inc
Vironika LLC
Zambon Co SpA
Zata Pharmaceuticals Inc
Zikani Therapeutics Inc